Biogen Inc. vs Catalyst Pharmaceuticals, Inc.: SG&A Expense Trends

Biogen vs Catalyst: SG&A Expense Evolution

__timestampBiogen Inc.Catalyst Pharmaceuticals, Inc.
Wednesday, January 1, 201422323420004473654
Thursday, January 1, 201521131000008597010
Friday, January 1, 201619479000007910260
Sunday, January 1, 201719355000007304399
Monday, January 1, 2018210630000015875961
Tuesday, January 1, 2019237470000036881187
Wednesday, January 1, 2020250450000044233754
Friday, January 1, 2021267430000049628000
Saturday, January 1, 2022240360000058183000
Sunday, January 1, 20232549700000133710000
Monday, January 1, 20242403700000
Loading chart...

Igniting the spark of knowledge

SG&A Expense Trends: Biogen Inc. vs Catalyst Pharmaceuticals, Inc.

In the ever-evolving pharmaceutical industry, understanding the financial strategies of key players is crucial. Biogen Inc. and Catalyst Pharmaceuticals, Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses from 2014 to 2023. Biogen, a leader in biotechnology, consistently allocated a significant portion of its budget to SG&A, peaking in 2021 with a 38% increase from 2017. This reflects its aggressive market expansion and strategic investments. In contrast, Catalyst Pharmaceuticals, a smaller player, demonstrated a remarkable 2,887% surge in SG&A expenses over the same period, highlighting its rapid growth and increased market presence. By 2023, Catalyst's SG&A expenses reached 13.4 million, a testament to its ambitious scaling efforts. These trends underscore the diverse financial strategies within the pharmaceutical sector, offering insights into how companies prioritize operational and market expansion.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025